BBIO insider notice: 120,000 shares (~$6.51M) set for 10/08/2025

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) submitted a Form 144 notice for a proposed sale of 120,000 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $6,506,400, scheduled approximately on 10/08/2025 and to be executed on NASDAQ. The shares were acquired on 03/26/2016 in a conversion of management incentive units. The filer disclosed multiple prior 10b5-1 sales over the past three months from related trusts and an individual, with individual trade sizes typically of 20,000 shares and one sale of 26,156 shares, generating proceeds in the $0.92M–$1.28M range per transaction.

The filing includes the standard Rule 144 representation that the seller does not possess undisclosed material adverse information and notes reliance on written trading plans where applicable.

Positive

• Seller used 10b5-1 plans, indicating pre‑arranged, rule‑compliant selling
• Shares originated from a 2016 conversion, showing long-term holding before sale

Negative

• Proposed sale of 120,000 shares (~$6.51M) could add notable near‑term supply
• Multiple recent 10b5-1 sales from related accounts total substantial volume in three months

Insights

Securities Trading Specialist

Large insider sale scheduled; multiple recent 10b5-1 plan executions.

The notice shows a proposed sale of 120,000 shares valued at $6,506,400 on or about 10/08/2025, executed through a major broker. The shares were originally acquired via conversion of management incentive units on 03/26/2016, indicating these are long-held, previously restricted securities becoming available under Rule 144.

Related accounts executed several 10b5-1 sales in the prior three months, typically 20,000-share blocks and one 26,156-share trade, producing proceeds between $0.92M and $1.28M. Investors should note that clustered, rule‑based selling can increase near‑term supply; timing and execution method are the primary variables affecting market impact in the short term.

Corporate Governance Analyst

Disposition stems from management incentive conversion; filing includes required certifications.

The securities were acquired through a conversion of management incentive units in 2016, which suggests these shares originated from compensation arrangements. The filer attests they are not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption where applicable.

Repeated 10b5-1 sales by related trusts and an individual in recent months indicate a systematic liquidity program rather than ad hoc insider selling; monitor scheduled dates such as 10/08/2025 for cumulative selling volume impact.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	120000	6506400.00	191168504	10/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/26/2016	Conversion Management Incentives Units	Issuer			120000	03/26/2016	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/05/2025	20000	1061044.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/05/2025	20000	1061002.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/04/2025	20000	1026862.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	09/04/2025	20000	1026926.00
10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/20/2025	26156	1276925.46
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00
10b5-1 Sales for KUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being sold in the BridgeBio (BBIO) Form 144 filing?

The filing notifies a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be executed on or about 10/08/2025 on NASDAQ.

How were the 120,000 shares acquired?

The shares were acquired on 03/26/2016 through a conversion of management incentive units from the issuer.

Have related parties sold shares recently?

Yes. The filing lists multiple 10b5-1 sales over the past three months by related trusts and an individual, typically 20,000-share blocks and one 26,156-share sale, with gross proceeds between $0.92M and $1.28M per trade.

Which broker will handle the proposed sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY.

Does the filer claim to have material nonpublic information?

By signing the form, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.

On what exchange will the sale occur?

The proposed sale is scheduled to occur on NASDAQ.